文献速递前列腺增生与排尿功能障碍

经皮腓神经电神经调节与索利那新治疗初治膀胱过度活动症患者的前瞻性随机多中心试验

Prospective, Randomized, Multicenter Trial of Peroneal Electrical Transcutaneous Neuromodulation vs Solifenacin in Treatment-naïve Patients With Overactive Bladder.
PubMed 文献 · J Urol · 2022-12-29

该研究将77例初治女性膀胱过度活动症患者按2:1随机分配至每日经皮腓神经电神经调节组或索利那新5mg组治疗12周,主要终点为安全性。结果显示神经调节组治疗相关不良事件发生率为12%(6/51),显著低于索利那新组的48%(12/25)(P<.001),两组应答者比例在多个指标上相近。

要点

  • 经皮腓神经电神经调节组治疗相关不良事件6/51(12%),索利那新组12/25(48%),P<.001。
  • 紧迫感发作(PPIUS 3级)应答率:神经调节组87% vs 索利那新组74%。
  • 紧迫感发作(PPIUS 3+4级)应答率:神经调节组87% vs 索利那新组75%。

核心结论

  • 经皮腓神经电神经调节是治疗膀胱过度活动症安全有效的方法,与索利那新相比治疗相关不良事件发生率显著更低,获益-风险特征明显更好。

研究设计与样本

  • 前瞻性、随机、多中心试验,共筛查120例患者,其中77例按2:1随机分配至12周每日经皮腓神经电神经调节组或索利那新5mg组。
  • 77例随机患者中71例完成研究。
  • 主要终点为安全性;疗效评估包括应答者比例(膀胱日记变量较基线减少≥50%)、OAB-V8问卷、EQ-5D问卷及治疗12周后的治疗满意度。

主要发现

  • 经皮腓神经电神经调节组6/51(12%)患者报告治疗相关不良事件,索利那新组12/25(48%)(P<.001)。
  • 其他安全性终点未见有临床意义的改变。
  • 紧迫感发作(PPIUS 3级)应答者比例:神经调节组87% vs 索利那新组74%。
  • 紧迫感发作(PPIUS 3+4级)应答者比例:神经调节组87% vs 索利那新组75%。
  • 紧迫性尿失禁应答者比例:神经调节组90% vs 索利那新组94%。

关键数值与推荐

  • 主要终点安全性:经皮腓神经电神经调节组治疗相关不良事件6/51(12%) vs 索利那新组12/25(48%),P<.001。
  • 应答者定义:膀胱日记变量较基线减少≥50%。
  • 紧迫感发作(PPIUS 3级)应答率:神经调节组87% vs 索利那新组74%。
  • 紧迫感发作(PPIUS 3+4级)应答率:神经调节组87% vs 索利那新组75%。
  • 紧迫性尿失禁应答率:神经调节组90% vs 索利那新组94%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We investigated the safety and efficacy of peroneal electrical transcutaneous neuromodulation using the URIS neuromodulation system in a home-based setting in comparison with standard treatment using solifenacin in treatment-naïve female patients with overactive bladder. MATERIALS AND METHODS: A total of 120 patients were screened, of whom 77 were randomized in a 2:1 ratio to 12 weeks of treatment with daily peroneal electrical transcutaneous neuromodulation or solifenacin 5 mg. The primary endpoint was safety; efficacy assessments included proportion of responders, defined as subjects with ≥50% reduction in bladder diary-derived variables; Overactive Bladder-Validated 8-question Screener, and European Quality of Life-5 Dimensions questionnaire; and treatment satisfaction after 12 weeks of therapy. RESULTS: Seventy-one out of 77 randomized patients completed the study. In the peroneal electrical transcutaneous neuromodulation group 6/51 (12%) patients reported a treatment-related adverse event vs 12/25 (48%) in the solifenacin group (P < .001). No clinically significant changes were observed in any other safety endpoint. The proportions of responders in the peroneal electrical transcutaneous neuromodulation group vs the solifenacin group were 87% vs 74% with respect to Patient Perception of Intensity of Urgency Scale grade 3 urgency episodes, 87% vs 75% with respect to grade 3+4 urgency episodes, and 90% vs 94% with respect to urgency incontinence episodes. In post hoc analyses we observed significant improvement over time in multiple efficacy variables in both treatment arms. CONCLUSIONS: Peroneal electrical transcutaneous neuromodulation is a safe and effective method for overactive bladder treatment associated with a significantly lower incidence of treatment-related adverse events compared to solifenacin and a considerably better benefit-risk profile.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Krhut J, Rejchrt M, Slovak M, et al. Prospective, Randomized, Multicenter Trial of Peroneal Electrical Transcutaneous Neuromodulation vs Solifenacin in Treatment-naïve Patients With Overactive Bladder. J Urol. 2022. PMID: 36579932. doi:10.1097/JU.0000000000003141

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。